Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.
Wright
Jonathan L
JL
Department of Urology, University of Washington, WA, USA.
Lin
Daniel W
DW
Dewan
Puneet
P
Montgomery
R Bruce
RB
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D019046:Bone Marrow Neoplasms / Q000188:drug therapy / Q000556:secondary; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D006417:Hematuria / Q000209:etiology; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000209:etiology / Q000628:therapy; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000972:Antineoplastic Agents, Phytogenic; D017430:Prostate-Specific Antigen; D017239:Paclitaxel